You are here

SARC Clinical Trials

Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials (studies). A list of SARC trials is provided here with a brief description and patient accrual status. Additionally, the National Institutes of Health provides an online registry and results database of clinical studies conducted around the world at ClinicalTrials.gov.

Patient participating in sarcoma trial

Active SARC Trials

SARC028
A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas
Type of Sarcoma: Soft Tissue Sarcoma, Bone Sarcoma
Drug: Pembrolizumab
Accrual Status: Open, Not Accruing
Overall Study Principal Investigator:
Hussein Tawbi, MD
Associate Professor of Medicine
MD Anderson Cancer Center
SARC025/ESP1-SPORE03
A Phase I study of a combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in patients with previously treated incurable Ewing Sarcoma
Type of Sarcoma: Ewing Sarcoma
Drug: Niraparib and Temozolomide or Irinotecan
Accrual Status: Active
Overall Study Principal Investigator:
Sandra Strauss, MD, PhD
Senior Lecturer and Consultant Medical Oncologist
University College London, Cancer Institute

Rashmi Chugh, MD
Assistant Professor
University of Michigan
SARC024
A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing–like sarcomas
Type of Sarcoma: Refractory liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcomas
Drug: Regorafenib and placebo (for liposarcoma and osteogenic sarcoma only)
Accrual Status: Active
Overall Study Principal Investigator:
Robert Maki, MD, PhD
Professor Pediatrics, Hematology & Oncology
Hofstra-Northwell School of Medicine

Richard F. Riedel, MD
Associate Professor of Medicine
Duke University School of Medicine

Christopher W. Ryan, MD
Medical Oncologist
Oregon Health and Science University

Steven Attia, DO
Medical Oncologist
Mayo Clinic
SARC023
A Phase I/II trial of ganetespib in combination with the mTOR inhibitor sirolimus for patients with unresectable or metastatic malignant peripheral nerve sheath tumors
Type of Sarcoma: Phase I all unresectable soft tissue or bone sarcomas and Phase II unresectable malignant peripheral nerve sheath tumor (MPNST)
Drug: ganetespib and sirolimus
Accrual Status: Open, Not Accruing
Overall Study Principal Investigator:

AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Medical Center

SARC022
A phase 2 study of OSI-906 in pediatic and adult wild type gastrointestinal stromal tumors
Type of Sarcoma: gastrointestinal stromal tumors
Drug: OSI-906
Accrual Status: Open, Not Accruing
Overall Study Principal Investigator:

Margaret von Mehren, MD
Fox Chase Cancer Center

SARC021
A randomized phase 3, multicenter, open-label study comparing TH-302 in combination with doxorubicin vs. doxorubicin alone in subjects with locally advanced unresectable or metastatic soft tissue sarcoma
Type of Sarcoma: locally advanced or metastatic soft tissue sarcoma
Drug: TH-302 combined with doxorubicin vs. doxorubicin alone
Accrual Status: Open, Not Accruing
Overall Study Principal Investigator:
William Tap, MD
Memorial Sloan-Kettering Cancer Center
SARC020
A Phase IIb/III multicenter study comparing the efficacy of trabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
Type of Sarcoma: advanced or metastatic untreated soft tissue sarcoma
Drug: trabectedin infused to doxorubicin
Accrual Status: Open, Not Accruing
Overall Study Principal Investigator:
James E. Butrynski, MD
Dana-Farber Cancer Institute
SARC018_SPORE02
A Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse Following Prior Treatment with Gemcitabine-Containing Therapy
Type of Sarcoma: Metastatic Leiomyosarcoma
Drug: Mocetinostat & Gemcitabine
Accrual Status: Open, Not Accruing
Overall Study Principal Investigator:
Shreyas Patel, MD
Co-Principal Investigator
MD Anderson Cancer Center

Edwin Choy, MD, PhD
Co-Principal Investigator
MGH, Dana Farber/Harvard Cancer Center
Division of Hematology Oncology
 
SARC016
Phase 2 study of everolimus in combination with bevacizumab in patients with sporadic and neurofibromatosis type 1 related refractory malignant peripheral nerve sheath tumors
Type of Sarcoma: malignant peripheral nerve sheath tumor (MPNST) either sporadic or NF1 associated
Drug: bevacizumab and everolimus
Accrual Status: Open, Not Accruing
Overall Study Principal Investigator:

Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute

SARC012
A placebo-controlled study of saracatinib (AZD0530) in patients with recurrent osteosarcoma localized to the lung
Type of Sarcoma: Osteosarcoma
Drug: saracatinib and placebo
Accrual Status: Open, Not Accruing
Overall Study Principal Investigator:

Melinda Merchant, MD, PhD
Staff Clinician, Pediatric Oncology Branch
National Cancer Institute

SARC009
A Phase 2 Trial of dasatinib in advanced sarcoma
Type of Sarcoma: Leiomyosarcoma, liposarcoma, MFH/pleomorphic undifferentiated sarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, osteosarcoma (skeletal or extraosseous), chondrosarcoma, ewing’s, alveolar soft part sarcoma, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma/solitary fibrous tumor, gastrointestinal stromal tumors (GIST)
Drug: Dasatinib
Accrual Status: Open, Not Accruing
Overall Study Principal Investigator:

Scott Schuetze, MD, PhD
University of Michigan

Closed SARC Trials

SARC019
A randomized, phase 3 study of dose escalation versus no dose escalation of Imatinib in metastatic GIST patients with Imatinib trough levels less than 1100 nanograms/mL
Type of Sarcoma: Metastatic GIST
Drug: Imatinib
Accrual Status: Closed
SARC011
SARC Global Collaboration: A phase 2 trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyo
Type of Sarcoma: Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma
Drug: R1507
Accrual Status: Closed
SARC007
Phase 2 Trial of perifosine in patients with chemo-insensitive Sarcomas
Type of Sarcoma: Chondrosarcoma, extra-skeletal myxoid chondrosarcoma or alveolar soft part sarcoma
Drug: Perifosine
Accrual Status: Closed
SARC006
Phase 2 Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: Malignant peripheral nerve sheath tumors sporadic or NF1 associated
Drug: Adriamycin/ifosfamide and Adriamycin/etoposide
Accrual Status: Closed
SARC005
Adjuvant treatment of high risk uterine leiomyosarcoma with gemcitabine/docetaxel, followed by: a phase II multi-center trial
Type of Sarcoma: Uterine Leiomyosarcoma
Drug: Gemcitabine and Docetaxel
Accrual Status: Closed
SARC004
Study of a short course of neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
Type of Sarcoma: Dermatofirbrosarcoma Protuberans
Drug: Gleevec (Imatinib Mesylate)
Accrual Status: Closed
SARC003
Phase 2 study of sequential gemcitabine followed by docetaxel for recurrent Ewing’s sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma
Type of Sarcoma: Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma
Drug: Gemcitabine and Docetaxel
Accrual Status: Closed
SARC002
Phase 3 randomized trial of 120-minute infusion gemcitabine v. 90-minute infusion gemcitabine plus docetazel in unresectable soft tissue sarcoma: A multi-disciplinary trial of the North American sarcoma study group of the Connective Tissue Oncology Societ
Type of Sarcoma: Unresectable soft tissue sarcoma
Drug: Gemcitabine and Docetaxel
Accrual Status: Closed
SARC001
Phase 2 Trial of Imatinib Mesylate (Gleevec) in patients with soft tissue and bone sarcomas: a multi-disciplinary trial
Type of Sarcoma: Ewing's Family (including PNET), OsteosarcomaSynovial Sarcoma, Leiomyosarcoma, Rhabdomyosarcoma (including alveolar, embryonal and pleomorphic), Liposarcoma (all variants), Malignant Fibrous Histiocytoma, Peripheral Nerve Sheath (including MPNST, neurofibrosarcoma, schwannoma), Fibrosarcoma, Angiosarcoma (all variants), Desmoid Tumor, GI Stromal (c-kit negative only)
Drug: Imatinib Mesylate (Gleevec)
Accrual Status: Closed
Overall Study Principal Investigator
Overall Study Principal Investigator
Type of Sarcoma:
Drug:
Accrual Status: Active